Immunotherapy in the Treatment of Lung Cancer

Fiala, Ondřej; Šorejs, Ondřej; Pešek, Miloš; Fínek, Jindřich

doi:10.14735/amko20173s22

Cited by 8 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most lung‐originated cancers, referred to as primary lung cancer, occur in epithelial cells, which are thin and lie on the alveolar surfaces of the lung for gas exchange 3. Clinically, lung cancer is mainly divided into small‐cell lung cancer and non–small cell lung cancer 4,5. Despite the fact that significant progresses have been made in systemic oncology treatments, lung cancer prognosis is far from satisfactory, which drives the need for innovative therapies and methods to treat this disease.…”

Section: Introductionmentioning

confidence: 99%

Retracted: Ailanthone exerts an antitumor function on the development of human lung cancer by upregulating microRNA‐195

2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Background: Lung cancer is a common leading cause of cancer-related death worldwide. Ailanthone, a natural compound isolated from Chinese herb Ailanthus altissima, has been reported to exert antiproliferative effects on various cancer cells. Methods: The present study aimed to investigate the role of ailanthone in the lung cancer cells and the correlation between the ailanthone and microRNA (miR)-195. The cell viability, proliferation, and apoptosis were determined by cell counting kit-8 assay, bromodeoxyuridine incorporation method, annexin Vfluorescein isothiocyanate/propidium iodide assay, respectively. Apoptosis-and autophagy-related proteins, as well as regulatory factors in the signaling pathways, were analyzed by Western blot method. The expression of miR-195 was quantified by quantitative reverse transcription-polymerase chain reaction. Results:The results confirmed that ailanthone was involved in the lung cancer cell progress by inhibiting cell viability and proliferation, but promoted cell apoptosis and autophagy. We also found that ailanthone upregulated the expression of miR-195.Further, the downregulated miR-195 inhibited the apoptosis and autophagy induced by ailanthone. Moreover, our studies revealed that miR-195 inhibitor promoted the phosphorylation of PI3K, AKT, JAK, and STAT3, which was inhibited by ailanthone.Conclusion: All these findings suggest that ailanthone plays key roles in lung cancer progress and is closely correlated with miR-195 expression.

show abstract

Section: Introductionmentioning

confidence: 99%

Retracted: Ailanthone exerts an antitumor function on the development of human lung cancer by upregulating microRNA‐195

2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

show abstract

“…Although therapeutic advances, including surgical resection and chemoradiotherapy, have improved the prognosis of patients with lung cancer, the overall survival rates and quality of life remain unsatisfactory. The migration and invasion of cancer cells that results in metastasis presents the greatest challenge to clinical therapy (3). Hence, investigation of the molecular mechanisms of lung cancer cell invasion and migration may provide novel evidence to improve clinical therapy.…”

Section: Introductionmentioning

confidence: 99%

Tip60‑siRNA regulates ABCE1 acetylation to suppress lung cancer growth via activation of the apoptotic signaling pathway

Liang

et al. 2019

Exp Ther Med

View full text Add to dashboard Cite

Lung cancer is a leading cause of cancer-associated mortality and morbidity worldwide. Previous studies have suggested that ATP-binding cassette transporter E1 (ABCE1) acetylation is upregulated in the tissues and cells of lung cancer and is associated with the prognosis of patients with lung cancer. The aim of the present study was to investigate the association between Tat interactive protein 60 kDa (Tip60) expression and ABCE1 acetylation, and the effect of Tip60 on the biological functions of A549 lung carcinoma cells. The expression levels of Tip60 and ABCE1 acetylation were examined using western blot and co-immunoprecipitation (Co-IP) assays in normal bronchial epithelial (HBE) and human lung cancer (A549) cells. The expression of Tip60 then was downregulated in A549 cells using small interfering RNA. Wound healing and Transwell assays were used to assess cell invasion and migration. The biological effects of Tip60 in lung cancer cells were investigated using MTT and flow cytometric assays. Subsequently, tumor xenografts were established to observe the effect of Tip60 on lung cancer in vivo. Western blot and Co-IP assays were performed to investigate the mechanism of Tip60 in A549 cells. Tip60 expression and ABCE1 acetylation were upregulated in the lung cancer cells compared with the normal bronchial epithelial cells. Downregulation of Tip60 decreased the acetylation of ABCE1 and inhibited cell proliferation, invasion and migration. Furthermore, the downregulation of Tip60 activated the apoptotic pathway in order to achieve its suppressive function. In the xenografts, the tumor weight and volume were notably reduced due to the downregulation of Tip60 expression. The results of the present study strongly suggest that Tip60 is a novel target in the prevention and treatment of lung cancer.

show abstract

“…m 6 A score is a reliable tool that can be used to assess m 6 A-TME. TMB alone is not a good predictor for the effect of immune checkpoint inhibitors, and the combined m 6 A score can improve the ability of TMB to predict immunotherapy [ 25 – 27 ]. Further studies revealed that higher PD-L1 expression in low m 6 A received better immunotherapy, suggesting that the lymphoid infiltrating cells in the tumor microenvironment can enhance the efficacy of immune check blocking therapy, while stromal cells can exert an anti-immune check blocker effect.…”

Section: Discussionmentioning

confidence: 99%

Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma

Huang

2022

PLoS ONE

View full text Add to dashboard Cite

Object Recent studies have demonstrated the epigenetic regulation of immune responses. However, the potential role of N6-methyladenosine methylation (m6A) in the tumor microenvironment (TME) remains unknown. Method In this study, the m6A modification patterns of LUAD samples were comprehensively evaluated by combining TCGA and GEO data, while these modification patterns were systematically linked to the characteristics of immune infiltrating cells in TME. The m6A score was constructed using the principal component analysis algorithm to quantify the m6A modification mode of a single tumor. Result There were three distinct patterns of m6A modification identified. The characteristics of TME cell infiltration in these three patterns were highly consistent with these three immune phenotypes of the tumors, including immune rejection, immune-inflammatory, and immune inert phenotypes. Low m6A scores were characterized by immune activation and poor survival rate. Besides, m6A scores were associated with tumor mutational load (TMB) and were able to increase the ability of TMB to predict immunotherapy. Two immunotherapy cohorts confirmed that the patients with lower m6A scores demonstrated significant therapeutic advantages and clinical benefits. m6A modifications play an important role in the development of TME diversity. Assessing the m6A modification pattern of individual tumors can deepen the understanding as to the characteristics of TME infiltration and guide more effective immunotherapy strategies.

show abstract

Immunotherapy in the Treatment of Lung Cancer

Cited by 8 publications

References 25 publications

Retracted: Ailanthone exerts an antitumor function on the development of human lung cancer by upregulating microRNA‐195

Retracted: Ailanthone exerts an antitumor function on the development of human lung cancer by upregulating microRNA‐195

Tip60‑siRNA regulates ABCE1 acetylation to suppress lung cancer growth via activation of the apoptotic signaling pathway

Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma

Contact Info

Product

Resources

About